Figure 2.
ERBS subgroups are associated with clinical subtypes and patient outcome. (A) Average ATAC-seq signal (top and bottom) at ERBS subgroups across PAM50 breast cancer subtypes. Higher signals indicate higher chromatin accessibility. Significance of paired Wilcoxon test is indicated. Bottom panel shows signal normalized to basal subtype. (B) Proportion of ERBS subgroups overlapping with peaks associated to good (dark) or poor outcome (light) (Ross-Innes et al. 2012). (C) Mean ESR1 ChIP-seq signal at ERBS, from patients with good (dark) and poor (light) outcomes (Ross-Innes et al. 2012).
